Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of CVS Health Corp (NYSE: CVS) closed at $71.93 in the last session, up 0.53% from day before closing price of $71.55. In other words, the price has increased by $0.53 from its previous closing price. On the day, 3.59 million shares were traded. CVS stock price reached its highest trading level at $72.08 during the session, while it also had its lowest trading level at $71.5702.
Ratios:
We take a closer look at CVS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.09. For the most recent quarter (mrq), Quick Ratio is recorded 0.62 and its Current Ratio is at 0.80. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 0.93.
Leerink Partners Upgraded its Market Perform to Outperform on February 13, 2025, whereas the target price for the stock was revised from $55 to $75.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 20 ’25 when Finucane Anne A. bought 7,500 shares for $70.97 per share.
SANSONE GUY P bought 1,570 shares of CVS for $100,009 on Jun 05 ’25. The Director now owns 12,007 shares after completing the transaction at $63.70 per share. On May 02 ’25, another insider, ROBBINS LARRY, who serves as the Director of the company, sold 2,276,068 shares for $67.86 each. As a result, the insider received 154,444,758 and left with 9,670,731 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVS now has a Market Capitalization of 91230978048 and an Enterprise Value of 159953715200. As of this moment, CVS’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.07, and their Forward P/E ratio for the next fiscal year is 10.04. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.39. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.24 while its Price-to-Book (P/B) ratio in mrq is 1.18. Its current Enterprise Value per Revenue stands at 0.416 whereas that against EBITDA is 11.447.
Stock Price History:
The Beta on a monthly basis for CVS is 0.62, which has changed by 0.26259434 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, CVS has reached a high of $72.51, while it has fallen to a 52-week low of $43.56. The 50-Day Moving Average of the stock is 9.40%, while the 200-Day Moving Average is calculated to be 17.10%.
Shares Statistics:
According to the various share statistics, CVS traded on average about 7.57M shares per day over the past 3-months and 6125060 shares per day over the past 10 days. A total of 1.27B shares are outstanding, with a floating share count of 1.27B. Insiders hold about 0.16% of the company’s shares, while institutions hold 87.65% stake in the company. Shares short for CVS as of 1755216000 were 16664640 with a Short Ratio of 2.20, compared to 1752537600 on 13670187. Therefore, it implies a Short% of Shares Outstanding of 16664640 and a Short% of Float of 1.3300001000000001.
Dividends & Splits
The forward annual dividend rate for CVS is 2.66, which was 2.66 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.0371768The stock’s 5-year Average Dividend Yield is 3.15. The current Payout Ratio is 72.76% for CVS, which recently paid a dividend on 2025-07-22 with an ex-dividend date of 2025-07-22. Stock splits for the company last occurred on 2005-06-07 when the company split stock in a 2:1 ratio.
Earnings Estimates
The current assessment of CVS Health Corp (CVS) involves the perspectives of 22.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.94, with high estimates of $1.06 and low estimates of $0.87.
Analysts are recommending an EPS of between $6.5 and $6.03 for the fiscal current year, implying an average EPS of $6.3. EPS for the following year is $7.15, with 28.0 analysts recommending between $7.8 and $6.49.
Revenue Estimates
According to 15 analysts, the current quarter’s revenue is expected to be $98.66B. It ranges from a high estimate of $100.1B to a low estimate of $97.33B. As of the current estimate, CVS Health Corp’s year-ago sales were $95.43BFor the next quarter, 15 analysts are estimating revenue of $100.98B. There is a high estimate of $102.82B for the next quarter, whereas the lowest estimate is $99.58B.
A total of 19 analysts have provided revenue estimates for CVS’s current fiscal year. The highest revenue estimate was $397.34B, while the lowest revenue estimate was $390.58B, resulting in an average revenue estimate of $393.16B. In the same quarter a year ago, actual revenue was $372.81BBased on 24 analysts’ estimates, the company’s revenue will be $408.49B in the next fiscal year. The high estimate is $430.06B and the low estimate is $389.3B.
